Logo
Make a donation
Make a donation

Department of clinical hematology

...

Olivier Hermine

 

Email
Stéphanie CHAMBAUD

Didier Bouscary

Head of the Cochin site

Email
Stéphanie CHAMBAUD

Access and contact

Cochin–Port Royal Hospital

27 rue du Faubourg Saint Jacques

75014 Paris

Diseases managed

Acute lymphoblastic leukemia

Acute myeloid leukemia

Myelodysplastic syndromes

Chronic myelomonocytic leukemia

Myeloproliferative neoplasms

Other malignant hematological diseases, and benign haematological disorders

Acute lymphoblastic leukemia

Acute myeloid leukemia

Myelodysplastic syndromes

Chronic myelomonocytic leukemia

Myeloproliferative neoplasms

Other malignant hematological diseases, and benign haematological disorders

Department activities

The Clinical Hematology department of Cochin–Port Royal Hospital is a comprehensive care unit dedicated to the management of adult patients with both malignant and benign haematological conditions. It forms part of the bi-site Haematology Department of GHU Paris Centre, under the leadership of Prof Olivier Hermine, which includes the haematology units of Cochin and Necker Hospitals.

The department is structured around three complementary units to ensure seamless and stage-appropriate care:

  • Intensive care unit, for patients requiring prolonged hospitalisation and close monitoring, including those with acute leukaemias, idiopathic aplastic anaemia, or undergoing CAR T-cell therapy.
  • Conventional inpatient unit, for patients in more stable phases of treatment.
  • Day hospital, where diagnostic procedures (bone marrow biopsies, aspirates), specific treatments (azacitidine, bispecific antibodies, ALL maintenance therapy, intrathecal chemotherapy), and transfusion support are administered.

This flexible organisation ensures continuity of care, allowing patients to transition between units as required throughout their therapeutic journey. The department also actively contributes to medical education by regularly hosting medical students and residents, and by supervising research training (MSc and PhD students).

The department works in close collaboration with the haematology laboratory and pathology department for integrated diagnostic pathways, and with the Cochin Institute, where fundamental and translational research is conducted—particularly in acute myeloid leukaemia and myelodysplastic syndromes—contributing to advances in pathophysiological understanding and therapeutic innovation.

Multidisciplinary Team Meetings

Weekly multidisciplinary team meeting involving all physicians of the department, nuclear medicine specialists, and pathologists, to discuss and define therapeutic strategies for patients with malignant haematological diseases.

Myeloid molecular oncology MDT held every 3 months, organised by Prof Olivier Kosmider and his team, in collaboration with clinicians.

Ad hoc video-conference MDT open to external centres, bringing together haematologists, obstetricians, pharmacologists, and anaesthetists to discuss the management of patients diagnosed with haematological malignancies during pregnancy.

Contact : rudy.birsen@aphp.fr / justine.decroocq@aphp.fr

Our clinical trials

Phase 2 study evaluating the combination of azacitidine and venetoclax in patients with high-risk CMML; sponsored by the French MDS Group.

En savoir plus

Three-arm randomised trial assessing novel immunotherapeutic agents and allogeneic stem cell transplantation in first-line treatment of adult acute lymphoblastic leukaemia; conducted by the GRAALL group.

En savoir plus

Open-label, multicentre, single-arm phase I/II study to assess dosing, safety, and preliminary efficacy of oral azacitidine combined with venetoclax in previously untreated high-risk MDS patients ineligible for transplantation; French MDS Group.

Phase I/III study evaluating the efficacy and safety of selinexor, a selective nuclear export inhibitor, in combination with ruxolitinib in treatment-naive patients with myelofibrosis.

Phase I/II multicentre trial assessing luspatercept in low-risk MDS without ring sideroblasts, refractory or ineligible to erythropoiesis-stimulating agents; French MDS Group.

En savoir plus

International, open-label, phase III randomised trial comparing ruxolitinib to hydroxycarbamide or interferon-alpha as first-line therapy in high-risk polycythaemia vera; sponsored by the University of Birmingham.

En savoir plus

Phase I/II trial assessing the addition of sulfasalazine to standard induction therapy in patients aged ≥60 years newly diagnosed with AML.

Team members

Dr WILLEMS Lise
Consultant, Head of the Inpatient Unit
Dr DECROOCQ Justine
Consultant, Head of the Intensive Care Unit
Dr VIGNON Marguerite
Consultant, Head of the Day Hospital
Dr FRANCHI Patricia
Associate Practitioner
Dr MIEKOUTIMA Elsa
Contracted Consultant
Dr DEAU Bénédicte
Consultant
Dr QUINT Laurent
Associate Practitioner
Pr BOUSCARY Didier
Professor of Medicine, University Consultant
Dr BOUTBOUL David
Associate Professor, University Consultant
Dr BIRSEN Rudy
Associate Professor, University Consultant
Dr KNAPP Silène
Clinical Fellow
Dr ROUPIE Anne-Laure
Clinical Fellow
Dr RODIER Cyrielle
Clinical Fellow

Job offers

Personnel médical

Registered nurse

Registered nurse (12h shifts, day or night) – Inpatient or intensive care units in haematology.

Download the PDF
Personnel médical

Nursing assistant

Nursing assistant (12h shifts, day-dominant with 3-month night rotation) – Inpatient and intensive care haematology units.

Download the PDF
Personnel médical

Medical administrative assistant

Download the PDF